Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Vsevolod Matveev, Sophie Wildsmith(AstraZeneca (United Kingdom)), Inkeun Park(Asan Medical Center), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Yohann Loriot(Institut Gustave Roussy), Michiel S. van der Heijden(Zorginstituut Nederland), Natasha Angra(AstraZeneca (United States)), Ignacio Durán(Instituto de Biomedicina de Sevilla), Wendy J. Levin(AstraZeneca (United States)), Howard Gurney(Radboud University Nijmegen), Aristotelis Bamias(National and Kapodistrian University of Athens), Daniel P. Petrylak(Yale University), Se Hoon Park(Samsung Medical Center), Hans M. Westgeest(Amphia Ziekenhuis), Jae‐Lyun Lee(Ulsan College), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Joaquim Bellmunt(Dana-Farber Cancer Institute), Yves Fradet(Centre hospitalier universitaire de Québec), André P. Fay(Hospital São Lucas da PUCRS), Iwona Skoneczna, Martin Bögemann(University Hospital Münster), Cristina Suárez(Complejo Hospitalario de Salamanca), Osamu Ogawa(Kyoto University Hospital), Yen‐Chuan Ou(Tungs' Taichung MetroHarbor Hospital), Bernhard J. Eigl(BC Cancer Agency), Philip He(AstraZeneca (Japan)), Som D. Mukherjee(Juravinski Cancer Centre), Aude Fléchon(Institut Català d'Ornitologia), Ashok Gupta
Cited by 502
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k